212838-91-0Relevant academic research and scientific papers
SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF
-
Paragraph 0050, (2020/06/10)
An adjuvant formulation includes a monophosphoryl Lipid A (MPLA) analogue, a Pam3CSK4 analogue, or a muramyldipeptide (MDP) analogue, or combinations thereof. The adjuvant may be formulated in soluble form or in a nanoparticle, such as polylactic glycolic acid nanoparticles. A vaccine formulation comprises the adjuvant formulation and an immunogen. Methods of vaccinating an animal include delivering the vaccine formulation to the animal.
An efficient synthesis of sulfobacin A (flavocristamide B), sulfobacin B, and flavocristamide A
Shioiri, Takayuki,Irako, Naoko
, p. 9129 - 9142 (2007/10/03)
Sulfobacin A (flavocristamide B, 1), sulfobacin B (2), and flavocristamide A (3), biologically active sulfonolipids, have been efficiently synthesized utilizing the asymmetric aldol reaction of the Schiff base 8 derived from glycine ester and (+)-2-hydroxy-3-pinanone (HyPN). (C) 2000 Elsevier Science Ltd.
Total synthesis of sulfobacin A (flavocristamide B)
Irako, Naoko,Shioiri, Takayuki
, p. 5793 - 5796 (2007/10/03)
Sulfobacin A (1), a novel von Willebrand factor receptor antagonist isolated from the culture broth of Chryseobacterium sp. NR 2993, was efficiently synthesized for the first time.
